DOBI Medical Holds 2nd Annual International Symposium
Mahwah, NJ, November 2, 2005 – DOBI Medical International, Inc. (DBMI.OB) engaged The Investor Relations Group of New York (IRG) for its corporate financial and public relations.
Phillip Thomas, CEO of DOBI Medical International, said, “At a time of increased awareness of the role of mammography, DOBI Medical’s ComfortScan® system may enable an improved diagnosis of cancer through the identification of abnormal neovascularization associated with tumors, especially for women under 50.”
“We believe that IRG is strategically positioned to help us explain the benefits of our ComfortScan system, which is currently under clinical trials as an adjunct to mammography,” explained Thomas.
Dian Griesel, Ph.D., founder and CEO of The Investor Relations Group, said, “We welcome DOBI Medical’s confidence in our ability to effectively communicate to the financial community and the media the importance of its dynamic optical breast-imaging system.”
About DOBI Medical International,
For more information on DOBI Medical, go to igaot.pt.
About The Investor Relations Group
CAUTIONARY STATEMENT FOR FORWARD-LOOKING STATEMENTS
Statements contained in this press release may contain
information that includes or is based upon certain "forward-looking
statements" relating to our business. These forward-looking statements
represent management's current judgment and assumptions, and can be
identified by the fact that they do not relate strictly to historical or
current facts. Forward-looking statements are frequently accompanied by
the use of such words as "anticipates," "plans," "believes," "expects,"
"projects," "intends," and similar expressions. Such forward-looking
statements involve known and unknown risks, uncertainties, and other
factors, including without limitation, those relating to our ability to
timely and successfully complete our patient clinical trials; our
ability to timely and successfully complete and submit our premarket
approval application to the FDA; the timely and final approval by the
FDA of our ComfortScan system as a adjunct to mammography, which
approval in the U.S. cannot be assured; the success of product
development and research efforts; our ability to timely meet U. S. and
foreign government laws and industry standards; our ability to meet U.S.
and foreign medical device quality regulation standards required to
maintain our CE Mark, and ISO, UL and FDA export certifications; our
ability to timely deliver our products into international markets; the
acceptance and use of our ComfortScan system by physicians, imaging
clinics, and patients; and our ability to obtain third party
reimbursement from U.S. and foreign government and private payers.
For further information:
DOBI Medical International